OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

by admin | 15th August 2023 | News

London and New York, NY, August 15 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market,...

Recent Posts

  • OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
  • OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
  • OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
  • OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
  • OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023